Candel Therapeutics, Inc.
CADL$245M
Micro CapNASDAQBiological Products, (No Diagnostic Substances)🇺🇸North AmericaNEEDHAM38 employees
Drugs in Pipeline
3
Phase 3 Programs
1
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
CADL News
Catalyst Timeline
1 upcoming, 1 past
Phase 2Next
✓Positiveaglatimagene besadenovec + valacyclovir Phase 2 Results Expected
June 2026~EstimatedAglatimagene besadenovec + valacyclovir30
Primary completion for aglatimagene besadenovec + valacyclovir trial (NCT07332000) in Prostate Cancer Patients Treated by Radiotherapy
extended survival reported
SourceDrug Pipeline
Aglatimagene besadenovec + valacyclovir
Prostate Cancer
aglatimagene besadenovec
Prostate Cancer
CAN-2409
Malignant Glioma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Aglatimagene besadenovec + valacyclovir | Phase 3 | Prostate Cancer | - | - |
aglatimagene besadenovec | Phase 2 | Prostate Cancer | - | - |
CAN-2409 | Phase 2 | Malignant Glioma | - | - |
Source: CatalystAlert database (ClinicalTrials.gov, SEC EDGAR)
Market-Implied Move
Regulatory Approvals
Get Catalyst Alerts
Receive weekly digests of upcoming catalysts
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply